Social vulnerability and gastrointestinal cancer mortality among United States counties.

Authors

null

Syed Arsalan Ahmed Naqvi

Mayo Clinic, Phoenix, AZ;

Syed Arsalan Ahmed Naqvi , Yusra Saleem , Kunwer Sufyan Faisal , Mahnoor Islam , Ahsan Ayaz , Hafsah Ijaz , Komal Khan , Syeda Zainab Kazmi , Muhammad Daim Bin Zafar , Bassam Bassam Sonbol , Zhaohui Jin , Safi U. Khan , Irbaz Bin Riaz

Organizations

Mayo Clinic, Phoenix, AZ; , Dow Medical College, Karachi, Pakistan; , Ziauddin Medical University, Karachi, Pakistan; , Dow University of Health Sciences, Karachi, Pakistan; , Mayo Clinic, Karachi, AZ; , Nishtar Medical University, Multan, Pakistan; , Xinjiang Medical University, Xinjiang, China; , Division of Medical Oncology, Mayo Clinic, Rochester, MN; , Guthrie Healthcare System, Sayre, PA; , Dana-Farber Cancer Institute, Boston, MA;

Research Funding

No funding received
None.

Background: The impact of socioeconomic status on gastrointestinal (GI) cancer mortality in the United States (US) is not well-established. We hypothesized that socially vulnerable populations have disproportionately higher mortality rates. Hence, we assessed the association of the social vulnerability index (SVI) with GI cancer mortality across US counties. Methods: Social vulnerability indices were obtained from the agency for toxic substances and disease registry (ATSDR) from 2014-2018 to compute percentile ranking scores (PRS: ranging from 0-1) for each US county. PRS were further categorized into quartiles (Q: 1st: 0-0.25 [least vulnerable]; 4th:0.75-1.00 [most vulnerable]). The wide-ranging online data for epidemiological research (WONDER) database was queried to abstract county-level age-adjusted mortality rates (AAMR) per 100,000 person-years (PY) for populations diagnosed with GI cancers. AAMRs were then linked with quartile rankings. Rate ratios (RR) of AAMRs between 4th and 1st Q were subsequently estimated with 95% confidence intervals using population-weighted, Poisson regression. Results: A total of 3142 counties were included in this analysis. The AAMR for overall deaths (OD) and premature deaths (PD; defined as death at age <65) in the GI cancer population was 53.8 and 17.7 per 100,000 PY. A gradient increase in GI cancer-related mortality was observed from 1st Q to 4th Q (OD: 49.2 vs 59.3; PD: 14.1 vs 21.3). This stepwise increase in AAMR over the quartiles was consistent across gender, different racial/ethnic subgroups, and rural/urban categories of counties. The AAMRs for OD were significantly higher in the 4th Q as compared to the 1st Q for gastric (RR: 1.67 [95% CI, 1.51-1.86]), hepatocellular including intrahepatic biliary (1.52 [1.45-1.61]), colorectal (1.21 [1.16-1.26]) and biliary (1.17 [1.06-1.28]) cancer. Similarly, significantly higher AAMRs for PD were observed in 4th Q vs1st Q for gastric (1.81 [1.60-2.05]), hepatocellular including intrahepatic biliary (1.78 [1.58-2.00]), biliary (1.64 [1.35-1.99]), colorectal (1.29 [1.21-1.39]) and pancreatic (1.16 [1.07-1.25]) cancer. However, no significant differences were observed for esophageal and small intestinal cancers. Men with gastric (1.58 [1.41-1.78]) and hepatocellular cancer (1.54 [1.43-1.66]), non-Hispanic Black population (1.54 [1.31-1.80]) with hepatocellular cancer, and Hispanic population with colorectal cancer (1.50 [1.31-1.72]) were observed to have higher overall mortality in the 4th Q compared to the 1st Q. The findings were similar for premature mortality. Conclusions: Population-level data suggests that the US counties with higher socio-economic adversities may be at an increased risk of GI cancer-related mortality. Investigations using patient-level data are required to probe the impact of socioeconomic vulnerabilities on cancer-related mortality.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Cancer Disparities

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 499)

DOI

10.1200/JCO.2023.41.4_suppl.499

Abstract #

499

Poster Bd #

A9

Abstract Disclosures

Similar Abstracts

First Author: Shaniza Haniff

Abstract

2024 ASCO Annual Meeting

Cost effectiveness of colorectal cancer screening in the Dominican Republic.

First Author: Yoanna S. Pumpalova

Abstract

2023 ASCO Genitourinary Cancers Symposium

Socioeconomic vulnerability and the risk of genitourinary cancer mortality among United States counties.

First Author: Anum Riaz